Switching To Letrozole Helps Breast Cancer Patients With Anastrozole-Related Rheumatologic Symptoms
Medical News Today
Article Date: 04 Jan 2010 - 0:00 PST
Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole therapy, researchers said at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
* Substances may block estrogen production
* Not meant to replace aromatase inhibitor medicines
By JoAnne Allen
WASHINGTON, Jan 5 (Reuters) - Enzyme-blocking chemicals in pomegranates may reduce the risk of estrogen-fueled breast cancers, U.S. researchers said on Tuesday.
An acid found in pomegranates appears to block aromatase, an enzyme that converts androgen to estrogen, a hormone that plays a role in the development...
WASHINGTON (Reuters) - A very low dose of estrogen might help women whose breast cancer has come back after treatment, researchers reported on Tuesday.
Even though most treatments are aimed at stopping estrogen from fueling tumors, the researchers said after years of this therapy the body may need some of the hormone to fight them off.
Their findings, published in the Journal of the American Medical Association, suggest a cheap...
High-dose Faslodex® Improves Time to Progression Compared with Arimidex® as Initial Therapy in Advanced Breast Cancer
Researchers affiliated with an international trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with Arimidex® (anastrozole) as initial therapy for hormone-positive, advanced breast cancer. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium December 10-14, 2008....
ARIMIDEX Offers Women Greater Protection Against HR+ Early Breast Cancer Returning In The 1st 2 Yrs
13 Mar 2009
"Anastrozole is the only aromatase inhibitor (AI) which has now been shown to prevent recurrences in women with hormone receptor positive early breast cancer both during the initial high-risk two years after surgery, and also well beyond the completion of treatment. In breast cancer there are no guarantees and we can't predict which women will experience...
